Don’t miss – Page 192 – Endpoints News

SIGN UP

Sangamo/Pfizer are catching up to BioMarin and Spark with a gene therapy for hemophilia A — can they leapfrog ahead?

4 years ago

J&J dumps $915M development deal with Hanmi as another Big Pharma abandons disaster-prone Korean drugmaker

4 years ago

Do exec departures portend clinical disasters? Analyst counts the examples

4 years ago

Going for it: GSK’s Hal Barron outlines a big PhIII program for rheumatoid arthritis — going head-to-head with giant rivals

4 years ago

Unum shares ricochet lower as premier drug slams into its second safety crisis, FDA slaps another hold on PhI

4 years ago

Ex-FDA commish Scott Gottlieb says he's 'very proud' of Pfizer post as top Dem attacks influence peddling

4 years ago

Bullish Amarin doubling sales force in fast run-up to the big FDA decision on Vascepa

4 years ago

Bayer, Versant back a $250M cell therapy startup on a quest to create off-the-shelf immuno-oncology therapies

4 years ago

Seducing Pfizer: How Array’s team patiently worked up the ladder to win an $11.4B bid from Albert Bourla

4 years ago

Scoring Pfizer v Sarepta: This round on Duchenne gene therapy goes to the little biotech, but the pharma Goliath has plenty of punch left

4 years ago

Scott Gottlieb tempts the FDA's fiercest critics with his leap onto Pfizer's board of directors

4 years ago

Turned back at the FDA, ImmunoGen is axing 220 staffers, selling programs and hunkering down for a new PhIII gamble

4 years ago

AstraZeneca challenges Roche on frontline SCLC after seizing an interim win — and Merck may not be far behind

4 years ago

Top analyst finds a silver lining in AbbVie’s $63B Allergan buyout — but there’s a catch

4 years ago

After raising $158M, this upstart's founders have star backers and plans to break new ground in gene therapy

4 years ago

AbbVie's $63B buyout spotlights the return of major M&A deals — despite the backlash

4 years ago

AbbVie seals $63B deal to buy a troubled Allergan — spelling out $1B in R&D cuts

4 years ago

In surprise switch, Bristol-Myers is selling off blockbuster Otezla, promising to complete Celgene acquisition — just later

4 years ago

Why would the FDA approve another controversial drug to spur a woman’s libido with these data? And why no expert panel review?

4 years ago

Which top 10 big pharmas have the most to gain — or lose — over the next 5 years?

4 years ago

HIV, pneumococcal — and what? Merck's unexpected pipeline highlight excites a little biotech

4 years ago

Who’s next in line to succeed Ken Frazier as CEO of the Keytruda-blessed Merck?

4 years ago

Sanofi's John Reed continues to reorganize R&D, cutting 466 jobs while boosting cancer, gene therapy research

4 years ago

A new number 1 drug? Keytruda tapped to top the 10 biggest blockbusters on the world stage by 2024

4 years ago

First page Previous page 189 190 191192193 194 195 Next page Last page